Lactobacillus rhamnosus cell lysate in the management of resistant childhood atopic eczema

Inflamm Allergy Drug Targets. 2010 Jul;9(3):192-6. doi: 10.2174/187152810792231896.


The number of children suffering from atopic eczema has increased over the past 30 years especially in children between the ages of 2 and 5 years. These is a significant group of eczematous children that are resistant to standard therapy. Babies and children with eczema suffer pain, irritation and disfigurement from the dermatitis. In this study, we have followed 14 cases of pediatric patients (ages of 8 months to 64 months) with a history of resistant eczema for a period of at least six months. All of these children received 300 mg to 500 mg standardized Lactobacillus rhamnosus cell lysate daily as an immunobiotic supplement. The results of this open label non-randomized clinical observation showed a substantial improvement in quality of life, skin symptoms and day- and nighttime irritation scores in children with the supplementation of Lactobacillus rhamnosus lysate. There were no intolerance or adverse reactions observed in these children. Lactobacillus rhamnosus cell lysate may thus be used as a safe and effective immunobiotic for the treatment and prevention of childhood eczema and possible other types of atopy (allergic diseases).

MeSH terms

  • Child, Preschool
  • Dermatitis, Atopic / prevention & control
  • Dermatitis, Atopic / therapy*
  • Drug Resistance
  • Humans
  • Infant
  • Lacticaseibacillus rhamnosus*
  • Probiotics / administration & dosage
  • Probiotics / therapeutic use*
  • Treatment Outcome